2 months ago
ANNX
AnalystsDerek ArchilaDerek Archila's Stock Forecasts
AnalystsDerek Archila
Analyst Ranking
Top 3%
#117 out of 4587 analysts
Average Return
+32.41%
Win Rate
51%48 out of 95
Risk vs Reward
Poor
Good
Derek Archila's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Cabaletta Bio IncCABA | +1,563.62% | $0.87 | $14.54 | 2022-09-13 - 2023-09-13 | Strong Buy |
Prometheus Biosciences IncRXDX | +604.58% | $27.52 | $193.90 | 2022-05-12 - 2023-05-12 | Strong Buy |
Prometheus Biosciences IncRXDX | +294.01% | $50.74 | $199.92 | 2022-08-28 - 2023-06-15 | Strong Buy |
Prometheus Biosciences IncRXDX | +185.97% | $33.50 | $95.80 | 2021-12-07 - 2022-12-07 | Strong Buy |
Ngm Biopharmaceuticals IncNGM | +167.08% | $11.30 | $30.18 | 2020-03-18 - 2021-03-19 | Strong Buy |
Derek Archila Analyst Color
Get additional color on Derek Archila's coverage of popular stocks
2 months ago
CABA
2 months ago
ASND
2 months ago
ZYME
5 months ago
MOR
8 months ago
IMVT
8 months ago
CABA
8 months ago
APLS
10 months ago
ARGX
10 months ago
IMVT
a year ago
MORF
a year ago
CABA
a year ago
ASND
a year ago
IMVT
2 years ago
ARGX
2 years ago
ASND
2 years ago
RXDX
2 years ago
ARGX
Derek Archila's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Annexon IncANNX | 3 | Strong Buy | $10.00 | +130.95% | Maintains | 4 days ago |
C4 Therapeutics IncCCCC | 4 | Hold | $8.00 | +40.85% | Maintains | 11 days ago |
Arvinas IncARVN | 4 | Strong Buy | $60.00 | +83.60% | Maintains | 11 days ago |
Zymeworks IncZYME | 3 | Strong Buy | $12.00 | +31.58% | Maintains | 16 days ago |
Ascendis Pharma AASND | 10 | Strong Buy | $262.00 | +116.31% | Maintains | 16 days ago |
Rhythm Pharmaceuticals IncRYTM | 4 | Strong Buy | $52.00 | +36.99% | Maintains | a month ago |
Anaptysbio IncANAB | 1 | Strong Buy | $56.00 | +123.37% | Initiates Coverage On | a month ago |
Cabaletta Bio IncCABA | 5 | Strong Buy | $35.00 | +183.40% | Maintains | 2 months ago |
Acelyrin IncSLRN | 2 | Hold | $13.00 | +196.13% | Maintains | 2 months ago |
Morphosys AgMOR | 4 | Hold | $18.25 | -3.95% | Downgrades | 2 months ago |
Ventyx Biosciences IncVTYX | 3 | Strong Buy | $16.00 | +238.27% | Upgrades | 2 months ago |
Argenx SeARGX | 6 | Strong Buy | $478.00 | +30.67% | Maintains | 3 months ago |
Nurix Therapeutics IncNRIX | 4 | Strong Buy | $20.00 | +20.55% | Maintains | 3 months ago |
Kymera Therapeutics IncKYMR | 5 | Hold | $26.00 | -25.61% | Downgrades | 5 months ago |
Blueprint Medicines CorpBPMC | 6 | Strong Buy | $115.00 | +9.57% | Maintains | 5 months ago |
Apellis Pharmaceuticals IncAPLS | 6 | Hold | $54.00 | +30.72% | Downgrades | 5 months ago |
Kezar Life Sciences IncKZR | 8 | Hold | $2.00 | +161.10% | Maintains | 6 months ago |
Celldex Therapeutics IncCLDX | 2 | Hold | $27.00 | -29.34% | Upgrades | 6 months ago |
Immunovant IncIMVT | 8 | Strong Buy | $48.00 | +56.35% | Maintains | 8 months ago |
Zentalis Pharmaceuticals IncZNTL | 2 | Strong Buy | $50.00 | +314.25% | Maintains | 9 months ago |
Dice Therapeutics IncDICE | 2 | Hold | $48.00 | +0.95% | Maintains | a year ago |
Morphic Holding IncMORF | 5 | Strong Buy | $80.00 | N/A | Maintains | a year ago |
Exelixis IncEXEL | 1 | Strong Buy | $23.00 | N/A | Initiates Coverage On | a year ago |
Incyte CorpINCY | 3 | Hold | $75.00 | N/A | Maintains | a year ago |
Monte Rosa Therapeutics IncGLUE | 2 | Strong Buy | $19.00 | N/A | Upgrades | a year ago |
Horizon Therapeutics Public Ltd CoHZNP | 2 | Hold | $116.50 | N/A | Downgrades | a year ago |
Prometheus Biosciences IncRXDX | 4 | Strong Buy | $71.00 | N/A | Maintains | 2 years ago |
Arena Pharmaceuticals IncARNA | 1 | Strong Buy | $71.00 | N/A | Initiates Coverage On | 2 years ago |
Esperion Therapeutics IncESPR | 1 | Hold | $20.00 | N/A | Downgrades | 3 years ago |
Lumos Pharma IncLUMO | 1 | Strong Buy | $24.00 | N/A | Upgrades | 3 years ago |
Momenta Pharmaceuticals IncMNTA | 2 | Hold | $52.50 | N/A | Downgrades | 4 years ago |
Principia Biopharma IncPRNB | 1 | Hold | $100.00 | N/A | Downgrades | 4 years ago |
Inventiva SaIVA | 1 | Strong Buy | $18.00 | N/A | Initiates Coverage On | 4 years ago |
Genfit SaGNFT | 1 | Strong Buy | N/A | N/A | Upgrades | 4 years ago |
Galapagos NvGLPG | 1 | Hold | $193.00 | N/A | Downgrades | 4 years ago |
Viela Bio IncVIE | 1 | Hold | $58.00 | N/A | Initiates Coverage On | 4 years ago |
Cymabay Therapeutics IncCBAY | 1 | Strong Buy | $8.00 | N/A | Upgrades | 4 years ago |
Oneok IncOKE | 1 | Strong Buy | $41.00 | N/A | Reiterates | 4 years ago |
Amarin Corp PLCAMRN | 2 | Hold | $8.00 | N/A | Maintains | 4 years ago |
Ngm Biopharmaceuticals IncNGM | 1 | Strong Buy | $32.00 | N/A | Maintains | 4 years ago |
Dbv Technologies SaDBVT | 2 | Hold | $6.00 | N/A | Downgrades | 4 years ago |
Vanda Pharmaceuticals IncVNDA | 4 | Hold | $29.00 | N/A | Downgrades | 5 years ago |
Heron Therapeutics IncHRTX | 2 | Buy | $50.00 | N/A | Maintains | 6 years ago |
Urogen Pharma LtdURGN | 1 | Buy | $51.00 | N/A | Maintains | 7 years ago |
Perrigo Co PLCPRGO | 1 | Buy | $88.00 | N/A | Initiates Coverage On | 7 years ago |
Pacira Biosciences IncPCRX | 1 | Hold | N/A | N/A | Initiates Coverage On | 7 years ago |
Zynerba Pharmaceuticals IncZYNE | 1 | Hold | N/A | N/A | Downgrades | 7 years ago |
Teva Pharmaceutical Industries LtdTEVA | 1 | Hold | N/A | N/A | Downgrades | 7 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.